Navigation Links
Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting
Date:12/2/2009

statements that can be identified by terminology such as "potential," "to present," "to show," "to demonstrate," "can," "will," "to explore," "pipeline," or similar expressions, or by express or implied discussions regarding potential new indications or labeling, or potential marketing approvals for the products described in this release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any of the products or additional indications or labeling described in this release will be submitted for approval or approved for sale in any market. Nor can there be any guarantee that any of these products will achieve any particular levels of revenue in the future. In particular, management's expectations regarding these products could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove inco
'/>"/>
SOURCE Novartis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
4. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
5. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
6. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
9. DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study
10. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
11. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... LOS ANGELES , Dec. 17, 2014 /PRNewswire/ ... that the US Patent and Trademark Office (USPTO) ... candidate ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting ... glioblastoma. The claims of US Patent No. 8,871,211, ... treating neural cancer by administering a dendritic cell ...
(Date:12/17/2014)... MARLBOROUGH, Mass. , Dec. 17, 2014 /PRNewswire/ ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced completion of enrollment in ... results from the 3-month observations confirmed the 1-month ... year:  Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:12/17/2014)... -- PCCA received the Autism Hope Alliance,s (AHA) ... seal for best practices in meeting needs in ... materials and goods that meet strict criteria and ... by autism often have unique physical or psychological ... in food and medicine – for instance casein, ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3
... 2011 IOD Incorporated, a leading provider of integrated ... today announced it has received the federal ... Meaningful Use certification of its PRISM platform for both ... deems the software capable of enabling providers to qualify ...
... Arecor Limited has entered into ... to assess Arecor,s advanced protein formulation technologies for ... drugs.  Under this agreement, Arecor will develop stable ... and peptide drug candidates developed by Lilly.  In addition, ...
Cached Medicine Technology:IOD Incorporated's PRISM™ Receives ONC-ATCB Certification by Drummond Group 2IOD Incorporated's PRISM™ Receives ONC-ATCB Certification by Drummond Group 3Arecor Forms Collaboration With Lilly to Develop Advanced Formulations of Protein Therapeutics 2
(Date:12/15/2014)... 2014 (HealthDay News) -- Expert pilots process visual information ... they make better decisions during landings, a new study ... techniques for pilots to master, and 36 percent of ... occur during final approach and landing. Researchers monitored ... moderately experienced pilots while they were at the controls ...
(Date:12/15/2014)... Kathy McAfee, America's Marketing Motivator, was announced a ... category of Best Blog 2014. McAfee received the top ... blog Networking Ahead which combines many different ... talent and influence through better networking, leadership and communication ... Ahead for Business, has been motivating readers for the ...
(Date:12/15/2014)... 15, 2014 In support of ... attention to restrictive state laws that may have ... this important area of public health policy. , ... the Integrity of Independent Review, contends that state ... independent peer review determinations can result in subpar ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Bacteroides is becoming ... only is it much more prevalent than coliforms, it cannot ... in the environment. , Key Benefits of the new ... fecal contamination , Eliminates false positives from coliforms ... and Sensitivity , Maintain the same sampling ...
(Date:12/15/2014)... La Jolla, Calif. (PRWEB) December 15, 2014 ... Roasters made the Coffee Review “Top 30 Coffees of 2014.” ... number two, and their Guji Zone Ethiopia at number 10. ... list twice. , Coffee Review’s selection is ranked on ... The Sumatra Ulos Batak scored 96 out of 100, and ...
Breaking Medicine News(10 mins):Health News:Study Shows Why Expert Pilots Are Experts 2Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2Health News:NAIRO Calls for Higher Quality Independent Peer Review By Ending Restrictive State Laws 2Health News:Bird Rock Coffee Roasters Ranks Second and Tenth in Coffee Review’s ‘Top 30 Coffees of 2014’ 2
... eCare, an initiative that employs information,and advanced technologies ... care, WILLIAMSBURG, Va., June 18 The ... and Mary proudly announces that,Professor Dorothea La "Chon" ... awards available to a faculty member in a ...
... source; New York City links 7 infections to salmonella ... number of people known to have fallen ill after ... 30 states plus the District of Columbia, U.S. health ... not due to new infections but mainly because some ...
... Corporation,(Nasdaq: AIRM ), the largest air medical ... Executive Officer Aaron Todd and Chief,Financial Officer Trent ... Conference in New York City on Tuesday, June ... can listen to the presentation via a live ...
... strike small percentage of patients , , WEDNESDAY, June 18 ... new side effect associated with the cancer drug Gleevec ... leukemia and gastrointestinal stromal tumors. , In a letter ... New England Journal of Medicine , the doctors describe ...
... seizures, SPOKANE, Wash., June 18 The Epilepsy,Foundation ... this Saturday, June 21 in Spokane at Riverfront Park ... from 9:30 am - 12:30 pm., "Everyone is ... with epilepsy," said Ryan Oelrich, Program Manager. "We are ...
... Berkeley The newly sequenced genome of a dainty, quill-like ... that vertebrates evolved over the past 550 million years through ... ,The late geneticist Susumu Ohno argued in 1970 ... evolution of higher organisms, and Ohno,s theory was the basis ...
Cached Medicine News:Health News:Professor Chon Abraham of the Mason School of Business at The College of William & Mary named Fulbright Scholar 2Health News:Professor Chon Abraham of the Mason School of Business at The College of William & Mary named Fulbright Scholar 3Health News:Professor Chon Abraham of the Mason School of Business at The College of William & Mary named Fulbright Scholar 4Health News:Professor Chon Abraham of the Mason School of Business at The College of William & Mary named Fulbright Scholar 5Health News:Tainted Tomato Cases Jump to 383 People in 30 states, D.C. 2Health News:Tainted Tomato Cases Jump to 383 People in 30 states, D.C. 3Health News:Cancer Drug Gleevec Linked to Muscle Damage 2Health News:Genome sequence of lancelet shows how genes quadrupled during vertebrate evolution 2Health News:Genome sequence of lancelet shows how genes quadrupled during vertebrate evolution 3Health News:Genome sequence of lancelet shows how genes quadrupled during vertebrate evolution 4
... The RapidAMP test is an immunochromatography ... It is,designed for qualitative determination of ... cut-off level of 1000 ng/mL. This ... the point of care,location and is ...
The RapidBARBITURATE test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of barbiturates and in human urine specimens above a cut-off level of 3...
... ACL TOP is a fully ... volume labs maximize labor resources and ... provides clotting, chromogenic and immunoturbidimetric testing ... routine and specialty assays. It's also ...
... Quality Analysis System) developed by Pablo Artal, ... first diagnostic tool for ophthalmology that provides ... system. Never before has an ophthalmologist had ... quality of vision. , ,OQAS works by ...
Medicine Products: